You are viewing the site in preview mode

Skip to main content

Articles

Page 1 of 7

  1. Fluoropyrimidines (FP) are the third most used chemotherapeutic drugs administered in solid tumors but have cardiotoxic side effects. We aimed to determine whether pre-chemotherapeutic cardiological assessment...

    Authors: Johanne D. Lyhne, Vibeke B. Hansen, Lone D. Vestergaard, Susanne E. Hosbond, Martin Busk, Mayooran Gnanaganesh, Else Maae, Birgitte M. Havelund, Torben F. Hansen, Signe Timm, Lars H. Jensen and Mads D. Lyhne
    Citation: Cardio-Oncology 2025 11:48
    Content type: Research Published on:

  2. Anthracycline-induced cardiomyopathy is a well-established adverse consequence in childhood cancer survivors. Altered mRNA expression in the peripheral blood has been found at the level of genes and pathways a...

    Authors: Purnima Singh, David K. Crossman, Changde Cheng, Patrick J. Trainor, Noha Sharafeldin, Xuexia Wang, Liting Zhou, Lindsey Hageman, Saro H. Armenian, Frank M. Balis, Douglas S. Hawkins, Frank G. Keller, Melissa M. Hudson, Joseph P. Neglia, Jill P. Ginsberg, Wendy Landier…
    Citation: Cardio-Oncology 2025 11:47
    Content type: Research Published on:

  3. This study aimed to investigate the impact of the proportion of hematologic malignancy patients in hospitals on the prognosis of chronic lymphocytic leukemia (CLL) patients undergoing cardiac surgery. Perioper...

    Authors: Meizhen Yi, Lanxin Hu, Jifang Zhou, Yali Ge, Cunhua Su and Fan Yang
    Citation: Cardio-Oncology 2025 11:46
    Content type: Research Published on:

  4. Cardiac involvement is the primary driver of death in systemic light chain (AL) amyloidosis. However, the early prediction of cardiac death risk in AL amyloidosis remains insufficient.

    Authors: Naidong Pang, Ying Tian, Hongjie Chi, Xiaohong Fu, Xin Li, Shuyu Wang, Feifei Pan, Dongying Wang, Lin Xu, Jingyi Luo, Aijun Liu and XingPeng Liu
    Citation: Cardio-Oncology 2025 11:45
    Content type: Research Published on:

  5. Trastuzumab is an effective treatment for HER2-positive cancers that has known cardiotoxic properties. Discovering biomarkers that assess cardiotoxicity risk before trastuzumab therapy is essential for protect...

    Authors: Jamila Mammadova, Alicia Richards, Adriana Gonzalez-Torriente, Evan R. Adler, Rachel J. Cruz, Stefanie Palfi, Dae Hyun Lee, Christine Sam, Mohammed Al-Jumayli, Anders Berglund, Jong Y Park, Mohammed Alomar and Jacob K. Kresovich
    Citation: Cardio-Oncology 2025 11:44
    Content type: Research Published on:

  6. The emerging discipline of cardio-oncology addresses the cardiovascular complications associated with cancer therapies. In sub-Saharan Africa (SSA), where both cardiovascular disease (CVD) and cancer-related m...

    Authors: Princess Afia Nkrumah-Boateng, Adam Ben-Jaafar, Allswell Naa Adjeley Boye, Pearl Ohenewaa Tenkorang, Toufik Abdul-Rahman and Wireko Andrew Awuah
    Citation: Cardio-Oncology 2025 11:43
    Content type: Correspondence Published on:

  7. Dexrazoxane, a putative iron chelator, is effective in preventing doxorubicin-induced cardiotoxicity. However, dexrazoxane is also a catalytic inhibitor of topoisomerase 2b (Top2b), a key mediator of doxorubic...

    Authors: Hui-Ming Chang, Jinn-Yuan Hsu, Chul Ahn and Edward T. H. Yeh
    Citation: Cardio-Oncology 2025 11:42
    Content type: Research Published on:

  8. Cardiac benign metastatic leiomyoma (BML) is a rare cardiac tumor that is usually asymptomatic, frequently misdiagnosed and may result in serious complications, including embolization, heart failure and death....

    Authors: Pankaj Garg, Mostafa Ali, Mohammad Alomari, J. Kenneth Schoolmeester, Mark Edgar, Carolyn K. Landolfo, Steven Attia and Kevin P. Landolfo
    Citation: Cardio-Oncology 2025 11:41
    Content type: Review Published on:

  9. Cardio-inflammatory immune related adverse events (irAEs) while receiving immune checkpoint inhibitor (ICI) therapy are particularly consequential due to their associations with poorer treatment outcomes. Eval...

    Authors: Michael Sayer, Hirofumi Hamano, Misako Nagasaka, Benjamin J. Lee, Jean Doh, Pranav M. Patel, Yoshito Zamami and Aya F. Ozaki
    Citation: Cardio-Oncology 2025 11:40
    Content type: Research Published on:

  10. Anthracyclines are essential in early breast cancer chemotherapy but pose long-term cardiotoxicity risks.

    Authors: Nattaya Poovorawan, Thiti Susiriwatananont, Chinachote Teerapakpinyo, Pajaree Chariyavilaskul, Piyada Sitthideatphaiboon, Luxica Jarutasnangkul, Monravee Tumkosit, Pairoj Chattranukulchai, Nonthikorn Theerasuwipakorn, Chatchawit Aporntewan, Shanop Shuangshoti, Sopark Manasnayakorn, Chanida Vinayanuwattikun, Yongkasem Vorasettakarnkij and Virote Sriuranpong
    Citation: Cardio-Oncology 2025 11:39
    Content type: Research Published on:

  11. Coronary artery calcification (CAC) scoring can be performed as a by-product of computed tomography (CT). CAC scoring may reflect the general cardiovascular risk profile of patients. The aim of the present stu...

    Authors: Hans-Jonas Meyer, Wolfram Pönisch, Jan Borggrefe and Alexey Surov
    Citation: Cardio-Oncology 2025 11:38
    Content type: Research Published on:

  12. Cardiotoxic, anthracycline-based therapies have high value in selected patients with breast cancer. We aimed to describe the effect of anthracycline plus taxane and single taxane chemotherapies on echocardiogr...

    Authors: Árpád Kézdi, Emese Szelke, Magdolna Dank, Dorottya Mühl, Gyöngyvér Szentmártoni, Gergely Szabó, Dominic Joseph Fogarasi, István Takács, Viktor J Horváth and Ádám G Tabák
    Citation: Cardio-Oncology 2025 11:37
    Content type: Research Published on:

  13. Cardiovascular mortality is a major cause of death in prostate cancer (PCa) survivors, yet tools for cardiovascular risk stratification in this population are lacking. Although hemoglobin A1c (HbA1c) is routin...

    Authors: Adithya K. Yadalam, Alexander C. Razavi, Sagar A. Patel, Chang Liu, Yan V. Sun and Anant Mandawat
    Citation: Cardio-Oncology 2025 11:36
    Content type: Correspondence Published on:

  14. Breast cancer (BC) patients face abnormal lipid metabolism and increased cardiovascular disease (CVD) risk due to endocrine therapies (ETs). This study evaluates CVD incidence and lipid abnormalities in Chines...

    Authors: Cheng Zeng, Hong Li, Wenna Wang, Lixi Li, Binliang Liu, Bo Lan, Qing Li, Wenjing Yang, Jiani Wang and Fei Ma
    Citation: Cardio-Oncology 2025 11:35
    Content type: Research Published on:

  16. Evidence suggests immune checkpoint inhibitor (ICI) can increase the risk of myocarditis. We investigated it in a large national cohort in China.

    Authors: Fu-Xiao Li, Jia-Xin Cai, Ji-Bin Li, Kong-Jia Luo, Shi-Yu Wang, Wei-Hua Meng, Feng Sha, Zhi-Rong Yang, Allan Hackshaw and Jin-Ling Tang
    Citation: Cardio-Oncology 2025 11:33
    Content type: Research Published on:

  17. Cardiotoxicity has become a major concern in cancer patients, especially those with lung cancer, as anti-tumor therapies can significantly affect patient survival and quality of life. This study aims to develo...

    Authors: Yumin Wang, Chunyan Huan, Huijuan Pu, Guodong Wang, Yan Liu, Xiuli Zhang, Chengyang Li, Jie Liu, Wanling Wu and Defeng Pan
    Citation: Cardio-Oncology 2025 11:32
    Content type: Research Published on:

  18. Over 1 million cases of prostate cancer are reported every year, and it is the second most common cancer in men. Androgen deprivation therapy (ADT) is a hallmark treatment for prostate cancer but is associated...

    Authors: Nishant P. Shah, Avinash Singh, Tia Higano, Derya Tilki, Neil Fleshner, Paul Nguyen, Chris Plummer, Juan Gomez Rivas, Kathleen Zhang, Ricardo Rendon, Alicia Morgans, Filipe Cirne, Darryl Leong, Daniel Lenihan and Renato D. Lopes
    Citation: Cardio-Oncology 2025 11:31
    Content type: Correspondence Published on:

  19. Myocarditis is a dreaded complication of immune-checkpoint inhibitor (ICI) therapy but challenging to diagnose. There are no published data comparing the two leading diagnostic criteria for ICI-related myocard...

    Authors: Milagros Pereyra Pietri, Juan M. Farina, Isabel G. Scalia, Ahmed K. Mahmoud, Michael Roarke, Beman Wasef, Cecilia Tagle-Cornell, Courtney R. Kenyon, Mohammed Tiseer Abbas, Nima Baba Ali, Kamal A. Awad, Niloofar Javadi, Nadera N. Bismee, Carolyn M. Larsen, Joerg Herrmann, Reza Arsanjani…
    Citation: Cardio-Oncology 2025 11:30
    Content type: Research Published on:

  21. Advances in the diagnosis and management of prostate cancer have significantly changed the disease landscape. While benefiting from better oncological outcomes, patients are now experiencing higher rates of no...

    Authors: Filipe Cirne, Michiel Sedelaar, Vivek Narayan, Ariane Macedo, Christopher Koo, Jeffrey de Jesus, Anthony Ng, Diogo Bastos, Alberto Briganti, Susan F. Dent, Nishant P. Shah, Renato D. Lopes, Daniel J. Lenihan and Darryl P. Leong
    Citation: Cardio-Oncology 2025 11:28
    Content type: Correspondence Published on:

  22. SERPINA3 recently emerged as potential prognostic biomarker in heart failure. In a population of cancer survivors with cancer therapy-related cardiac dysfunction (CTRCD) circulating SERPINA3 was elevated compa...

    Authors: Hanne M. Boen, Lobke L. Pype, Konstantinos Papadimitriou, Sevilay Altintas, Laure-Anne Teuwen, Sébastien Anguille, Kirsten Saevels, Anke Verlinden, Leen Delrue, Ward A. Heggermont, Matthias Bosman, Pieter-Jan Guns, Hein Heidbuchel, Caroline M. Van De Heyning, Emeline M. Van Craenenbroeck and Constantijn Franssen
    Citation: Cardio-Oncology 2025 11:27
    Content type: Research Published on:

  23. Immune checkpoint inhibitor(ICI) induced cardiac immune related adverse events are challenging to study; Leveraging large data bases like TriNetX global health network may provide needed insights.

    Authors: Aya F. Ozaki, Michael Sayer, Hirofumi Hamano, Misako Nagasaka, Benjamin J. Lee, Jean Doh, Ali Naqvi, Nareh Nowrouzi, Yoshito Zamami and Pranav M. Patel
    Citation: Cardio-Oncology 2025 11:26
    Content type: Correspondence Published on:

  25. Breast cancer survivors are at increased risk of cardiovascular events due to the cardiotoxic effects of cancer treatment. Exercise participation can lower the risk of various adverse cardiovascular health out...

    Authors: Oliver W.A. Wilson, Kaitlyn M. Wojcik, Camryn M. Cohen, Dalya Kamil, Gisela Butera, Charles E. Matthews, Christina M. Dieli-Conwright and Jinani Jayasekera
    Citation: Cardio-Oncology 2025 11:24
    Content type: Review Published on:

  26. Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2), is often the first line treatment for HER2 positive breast cancer. Although trastuzumab is effective, it has cardioto...

    Authors: Aditi Sharma, Maria E. Fierro, Samuel Governor, Aishwarya Kothare, Stella Pak, Karen Liu, Zuha Alam and Prince Otchere
    Citation: Cardio-Oncology 2025 11:23
    Content type: Research Published on:

  27. Anthracycline induced cardiomyopathy (AIC) is an important complication of cancer management. Recent findings showed that with early identification and intervention, AIC may be fully or partially reversible. E...

    Authors: Zac Forbes, Tegan Dunmall, Amanda Tey, Dominic Culligan and Pasquale L. Fedele
    Citation: Cardio-Oncology 2025 11:22
    Content type: Correspondence Published on:

  28. Cancer and cardiovascular diseases are the leading causes of mortality worldwide, as they share common risk factors and exacerbate cardiovascular outcomes when they coexist. This study aimed to assess the clin...

    Authors: Marta Sabaté-Tormos, Alfredo Bardají, Oscar M Peiró, Anna Carrasquer, German Cediel and Jose Luis Ferreiro
    Citation: Cardio-Oncology 2025 11:21
    Content type: Research Published on:

  29. For patients diagnosed with both lung cancer and severe coronary heart disease (CHD), the conflict between revascularization and lung cancer surgery remains to be settled to balance how to attenuate the cardio...

    Authors: Jing Zeng, Junyi Yu, Qiao Mei, Ye Yuan, Taiming Zhang, Longyong Mei, Lingling Huang, Yijie Hu, Bo Deng, Gengze Wu and Chunyu Zeng
    Citation: Cardio-Oncology 2025 11:20
    Content type: Research Published on:

  31. Cancer therapy-related cardiac dysfunction (CTRCD) is an important adverse effect in patients receiving potential cardiotoxic cancer therapies. Interpretation of cardiac troponin results can be affected by pre...

    Authors: Andrea Soosaipillai, Inbar Nardi-Agmon, Davor Brinc, Anselmo Fabros, Peter A. Kavsak, Paaladinesh Thavendiranathan and Ashley Di Meo
    Citation: Cardio-Oncology 2025 11:18
    Content type: Research Published on:

  32. Cancer-therapy related cardiac dysfunction (CTRCD) remains a significant cause of morbidity and mortality in cancer survivors. In this study, we aimed to identify differential plasma proteins and metabolites a...

    Authors: Jessica C. Lal, Michelle Z. Fang, Muzna Hussain, Abel Abraham, Reina Tonegawa-Kuji, Yuan Hou, Mina K. Chung, Patrick Collier and Feixiong Cheng
    Citation: Cardio-Oncology 2025 11:17
    Content type: Research Published on:

  33. Myocarditis is a potentially fatal condition, with a mortality rate of up to 50% in severe cases. Studies, including those by Nobel Laureate Honjo, have implicated autoantibodies against cardiac troponin I (cT...

    Authors: Shirley Xu, Swati D. Sonkawade, Badri Karthikeyan, Victoire-Grace Karambizi, Prachi S. Kulkarni, Sarmila Nepali, Saraswati Pokharel and Umesh C. Sharma
    Citation: Cardio-Oncology 2025 11:16
    Content type: Research Published on:

  34. More evidence-based strategies are needed for preventing and managing cancer treatment-related cardiovascular toxicity (CTR-CVT). Owing to the growing body of evidence supporting their cardioprotective role in...

    Authors: Carl Simela, J Malcolm Walker, Arjun K. Ghosh and Daniel H. Chen
    Citation: Cardio-Oncology 2025 11:15
    Content type: Review Published on:

  35. Tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor (VEGF) receptor signalling are used in cancer therapy to inhibit angiogenesis. Unfortunately, VEGF inhibitors are known to induce ...

    Authors: Dustin N. Krüger, Patrizia Pannucci, Callan D. Wesley, Cedric H. G. Neutel, Wim Martinet, Guido R. Y. De Meyer, Stephen J. Hill, Jeanette Woolard, Constantijn Franssen and Pieter-Jan Guns
    Citation: Cardio-Oncology 2025 11:14
    Content type: Research Published on:

  36. This study investigates the long-term cardiac effects of trastuzumab-based chemotherapy in early breast cancer (EBC) survivors. We extend the original MANTICORE trial which showed that angiotensin-converting e...

    Authors: Dina Labib, Mark Haykowsky, Emer Sonnex, John R. Mackey, Richard B. Thompson, D. Ian Paterson and Edith Pituskin
    Citation: Cardio-Oncology 2025 11:13
    Content type: Research Published on:

    The Editorial to this article has been published in Cardio-Oncology 2025 11:25

  37. Androgen deprivation therapy (ADT) is the cornerstone treatment strategy for men diagnosed with high-risk prostate cancer (PC) but may increase risk for major adverse cardiovascular events (MACE). We examined ...

    Authors: Alexander R. Lucas, Dustin Bastiach, Bassam Dahman, Asit K. Paul, Samina Hirani, Vanessa B. Sheppard, W. Gregory Hundley, Bhaumik B. Patel, Rhonda L. Bitting and Michael G. Chang
    Citation: Cardio-Oncology 2025 11:12
    Content type: Research Published on:

  38. Cancer survivors receiving doxorubicin may experience left ventricular ejection fraction (LVEF) decline during and following treatment; however, explanations for variations in decline beyond dosage differences...

    Authors: Arnethea L. Sutton, Nathaniel S. O’Connell, Alexander R. Lucas, Kristine C. Olson, Kerryn W. Reding, Vanessa B. Sheppard, Bonnie Ky, Kathryn J. Ruddy, Kathryn E. Weaver and W. Gregory Hundley
    Citation: Cardio-Oncology 2025 11:11
    Content type: Correspondence Published on:

  39. Cancer survivors are reported to be at a heightened risk of coronary artery disease (CAD) due to shared risk factors, potentially cardiotoxic cancer treatments and premature aging in survivors. Early identific...

    Authors: Cheng Hwee Soh, Joel Smith, Shristy Shrestha, Mark Nolan, Joshua Wong, Nitesh Nerlekar and Thomas H. Marwick
    Citation: Cardio-Oncology 2025 11:10
    Content type: Research Published on:

  40. Heart failure (HF) is associated with systemic inflammation and hypercatabolic syndrome, impacting body metabolism. The advanced lung cancer inflammation index (ALI) is a novel inflammatory and nutritional bio...

    Authors: Ahmed Mazen Amin, Ramy Ghaly, Hossam Elbenawi, Abdelrahman Ewis, Ubaid Khan, Khaled S. M. Elshaer, Mohamed Abuelazm, Basel Abdelazeem, Brijesh Patel, Farris K. Timimi and Islam Y. Elgendy
    Citation: Cardio-Oncology 2025 11:9
    Content type: Review Published on:

  41. Dexrazoxane has been studied for its ability to prevent anthracycline-induced cardiac dysfunction (AICD) in several trials but its use in clinical practice remains limited. This is related to the low to modera...

    Authors: Marijke Linschoten, Jesse Geels, Erik van Werkhoven, Heleen Visser-Wisselaar, Martine E. D. Chamuleau, Arco J. Teske, Lourens Robbers, Simone Oerlemans, Heleen Crommelin, Marleen Breems-de Ridder, Astrid Schut, Folkert W. Asselbergs and Anna van Rhenen
    Citation: Cardio-Oncology 2025 11:8
    Content type: Research Published on:

  42. Cardiovascular (CV) comorbidities and concurrent medications with risk of heart rate-corrected QT interval (QTc) prolongation can impact treatment decisions and safety discussions for patients with breast canc...

    Authors: Susan Dent, Avirup Guha, Heather Moore, Doris Makari, Rachael McCaleb, Irene Arias, Stella Stergiopoulos, Benjamin Li and Michael Fradley
    Citation: Cardio-Oncology 2025 11:7
    Content type: Research Published on:

  44. Breast cancer (BC) and cardiovascular disease (CVD) are prevalent comorbidities in aging populations. Advances in BC treatment have improved survival rates but increased the risk of CVD, particularly among you...

    Authors: Panagiotis Mallios, Mehdi Dehghan Manshadi, Laila Hubbert, Tajeri Aydin, Claudia Maes, Johanna Rantala, Annelie Liljegren, Narsis A. Kiani and Elham Hedayati
    Citation: Cardio-Oncology 2025 11:5
    Content type: Research Published on:

  45. With early detection and improvements in systemic and local therapies, millions of people are surviving cancer, but for some at a high cost. In some cancer types, cardiovascular disease now competes with recur...

    Authors: Anecita Fadol, Geraldine Lee, Valerie Shelton, Kelly C. Schadler, Asma Mohammed Younus, Mary Stuart, Lisa Nodzon and Edith Pituskin
    Citation: Cardio-Oncology 2025 11:4
    Content type: Research Published on:

  46. Fluoropyrimidines, including 5-fluorouracil and capecitabine, are the most common chemotherapeutic agents for colorectal carcinoma. Although previous studies have suggested varying degrees of cardiotoxicity wi...

    Authors: Chun-Ka Wong, Isaac Ho, Ali Choo, Rachel Lau, Ting-Fung Ma, Alston Conrad Ho-On Chiu, Tsun-Ho Lam, Minqing Lin, Ricky Wang-Hei Leung, Frankie Chor-Cheung Tam, Dominic Chi Chung Foo and Hung-Fat Tse
    Citation: Cardio-Oncology 2025 11:3
    Content type: Research Published on:

  47. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment outcomes. However, the response varies across different populations, and their use may lead to life-threatening cardiovascular (CV) even...

    Authors: Maor Tzuberi, Rafael Y. Brzezinski, Nir Flint, Moaad Slieman, Lior Zornitzki, Dana Viskin, Anna Rozenfeld Hemed, Barliz Waissengrin, Renana Barak, Inbal Golomb, Ido Wolf, Netanel Golan, Yan Topilsky, Shmuel Banai, Livia Kapusta and Michal Laufer-Perl
    Citation: Cardio-Oncology 2025 11:2
    Content type: Research Published on:

  48. Although anthracycline-related cardiotoxicity is widely studied, only a limited number of echocardiographic studies have assessed cardiac function in breast cancer survivors (BCSs) beyond ten years from anthra...

    Authors: Mali Sæter, Sara Hassing Johansen, Kristin Valborg Reinertsen, Lene Thorsen, Kristina Hermann Haugaa, Tormod Skogstad Nilsen and Sebastian Imre Sarvari
    Citation: Cardio-Oncology 2025 11:1
    Content type: Research Published on:

  49. The evolving field of oncology necessitates effective management of cancer-related cardiovascular diseases. In Saudi Arabia, the incidence of cancer is rising, and there is a critical need for cardio-oncology ...

    Authors: Hisham A. Badreldin, Nada Alsuhebany, Lama Alfehaid, Mohammed Alzahrani, Maha Aldoughaim, Abdullah M. Alrajhi, Jumanah Alsufyani, Dania Elsherif and Kanan Alshammari
    Citation: Cardio-Oncology 2024 10:93
    Content type: Research Published on:

  50. Cancer and cardiovascular diseases are leading causes of death worldwide. Among them, breast cancer is one of the most common malignancies in women, while atrial fibrillation is one of the most extensively stu...

    Authors: Xiaoxue Guo, Zheng Zuo, Xishu Wang, Ying Sun, Dongyang Xu, Guanghui Liu, Yi Tong and Zhiguo Zhang
    Citation: Cardio-Oncology 2024 10:92
    Content type: Review Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 3.2
    5-year Journal Impact Factor: N/A
    Source Normalized Impact per Paper (SNIP): 0.822
    SCImago Journal Rank (SJR): 0.958

    Speed 2024
    Submission to first editorial decision (median days): 13
    Submission to acceptance (median days): 100

    Usage 2024
    Downloads: 253,129
    Altmetric mentions: 271

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Cardio-Oncology

ISSN: 2057-3804

Contact us